News

AlphaLife Sciences has been named as a Major Contender in the Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2024, underscoring its performance and expertise in the sector. This prestigious evaluation assesses clinical data and analytics (D&A) platforms across the global life sciences industry, has positioned AlphaLife Sciences as a major force in the field. The achievement reflects the company’s unwavering commitment to its vision of accelerating affordable drug development through strategic investments and innovation in generative AI-powered clinical development solutions.

Everest Group’s PEAK Matrix® assessment is a proprietary framework for evaluating the relative market success and overall capability of technology and service providers based on their performance, experience, ability, and knowledge. The assessment categorizes 18 leading clinical D&A platform providers as Leaders, Major Contenders, and Aspirants based on market impact—measured by revenue, number of clients, and year-over-year growth—and vision and capability—measured by factors such as scale of operations, scope, technology, and innovation.

"We are honored to be recognized as a Major Contender in Everest Group's Life Sciences Clinical Data and Analytics Platforms PEAK Matrix® Assessment 2024," said Sharon Chen, Founder and CEO of AlphaLife Sciences. "This recognition validates our dedication to driving innovation in clinical development through generative AI-powered solutions. By leveraging cutting-edge technologies, we remain committed to accelerating drug development, improving efficiency, and making life-saving treatments more accessible worldwide."

About AlphaLife Sciences

AlphaLife Sciences, a leader in GenAI-driven clinical development, revolutionizes data management and automates medical and regulatory documentation through its AuroraPrime platform, delivering enhanced efficiency across therapeutic areas. Backed by the Microsoft for Startups Pegasus Program, Google for Startups, Nvidia Inception Program, and Johnson & Johnson Innovation JLABS, AlphaLife Sciences accelerates drug research and development, fast-tracking life-saving treatments for patients worldwide.

About Everest Group  Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.